Registry for Blue Light Cystoscopy with Cysview in bladder cancer
Blue Light Cystoscopy With Cysview® Registry
This study collects information on how well Blue Light Cystoscopy with Cysview works for finding bladder cancer compared to regular light methods in patients with suspected or known non-muscle invasive bladder cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 4400 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Photocure Industry-sponsored |
| Drugs / interventions | chemotherapy |
| Locations | 23 sites (Birmingham, Alabama and 22 other locations) |
| Trial ID | NCT02660645 on ClinicalTrials.gov |
What this trial studies
This registry collects data on the use of Blue Light Cystoscopy with Cysview in patients with known or suspected non-muscle invasive bladder cancer. It aims to evaluate the incremental detection rates of this technique compared to conventional white light cystoscopy across various patient populations. The study will also investigate how specific tumor characteristics and cytology results influence detection rates and performance metrics. By gathering this information, the registry seeks to enhance understanding of the effectiveness of Blue Light Cystoscopy in clinical practice.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years old with suspected or known non-muscle invasive bladder cancer.
Not a fit: Patients with porphyria, gross hematuria, or known hypersensitivity to hexaminolevulinate or aminolevulinate derivatives may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved detection rates of bladder cancer, potentially reducing recurrence and progression in patients.
How similar studies have performed: Other studies have shown promising results with similar approaches, indicating the potential effectiveness of Blue Light Cystoscopy.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult \>18 years old * Suspected or known non-muscle invasive bladder cancer on the basis of a prior cystoscopy Exclusion Criteria: * Porphyria * Gross hematuria * Known hypersensitivity to hexaminolevulinate or aminolevulinate derivatives
Where this trial is running
Birmingham, Alabama and 22 other locations
- The University of Alabama at Birmingham — Birmingham, Alabama, United States (Recruiting)
- Mayo Clinic — Phoenix, Arizona, United States (Recruiting)
- USC/Norris Comprehensive Cancer Center — Los Angeles, California, United States (Recruiting)
- University of California Los Angeles — Los Angeles, California, United States (Recruiting)
- VA Palo Alto Health Care System — Palo Alto, California, United States (Recruiting)
- University of California, San Francisco — San Francisco, California, United States (Recruiting)
- Sibley Memorial Hospital — Washington D.C., District of Columbia, United States (Recruiting)
- Emory University School of Medicine — Atlanta, Georgia, United States (Recruiting)
- Northwestern University — Chicago, Illinois, United States (Recruiting)
- Northshore University Health System — Evanston, Illinois, United States (Recruiting)
- Indiana University School of Medicine — Indianapolis, Indiana, United States (Recruiting)
- University of Kansas Medical Center — Kansas City, Kansas, United States (Recruiting)
- Johns Hopkins Medicine — Baltimore, Maryland, United States (Recruiting)
- University of Minnesota — Minneapolis, Minnesota, United States (Recruiting)
- NYU Langone's Perlmutter Cancer Center — New York, New York, United States (Recruiting)
- Stony Brook Urology — Stony Brook, New York, United States (Suspended)
- Ohio State University Wexner Medical Center — Columbus, Ohio, United States (Recruiting)
- Ohio State University — Columbus, Ohio, United States (Recruiting)
- Lexington Medical Center — West Columbia, South Carolina, United States (Recruiting)
- UT Southwestern — Dallas, Texas, United States (Recruiting)
- Michael E. DeBakey VA Medical Center — Houston, Texas, United States (Recruiting)
- University of Washington Medicine — Seattle, Washington, United States (Recruiting)
- Charleston Area Medical Center — Charleston, West Virginia, United States (Terminated)
Study contacts
- Principal investigator: Siamak Daneshmand, MD — University of Southern California
- Study coordinator: Chad McKee, PhD
- Email: chad.mckee@photocure.com
- Phone: (919) 780-0417
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.